Oncothyreon appoints new R&D vice president
This article was originally published in Scrip
Biotechnology company Oncothyreon, which specialises in the development of innovative therapeutic oncology products, has appointed Dr Scott Peterson as vice-president of R&D, effective August 1st. In his new role, Dr Peterson will oversee preclinical and non-clinical R&D activities at the company. Dr Peterson previously worked at Zymogenetics, where he served as director and department head of oncology research; prior to this, he held the role of principal scientist in oncology drug discovery at ICOS Corporation.